Literature DB >> 11602701

Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.

O Utermöhlen1, C Schulze-Garg, G Warnecke, R Gugel, J Löhler, W Deppert.   

Abstract

Protective immunity of BALB/c mice immunized with simian virus 40 (SV40) large T antigen (TAg) against SV40-transformed, TAg-expressing mKSA tumor cells is critically dependent on both CD8(+) and CD4(+) T lymphocytes. By depleting mice of T-cell subsets at different times before and after tumor challenge, we found that at all times, CD4(+) and CD8(+) cells both were equally important in establishing and maintaining a protective immune response. CD4(+) cells do not contribute to tumor eradication by directly lysing mKSA cells. However, CD4(+) lymphocytes provide help to CD8(+) cells to proliferate and to mature into fully active cytotoxic T lymphocytes (CTL). Depletion of CD4(+) cells by a single injection of CD4-specific monoclonal antibody at any time from directly before injection of the vaccinating antigen to up to 7 days after tumor challenge inhibited the generation of cytolytic CD8(+) lymphocytes. T helper cells in this system secrete the typical Th-1 cytokines interleukin 2 (IL-2) and gamma interferon. Because in this system TAg-specific CD8(+) cells secrete only minute amounts of IL-2, it appears that T helper cells provide these cytokines for CD8(+) T cells. Moreover, this helper effect of CD4(+) T cells in mKSA tumor rejection in BALB/c mice does not simply improve the activity of TAg-specific CD8(+) CTL but actually enables them to mature into cytolytic effector cells. Beyond this activity, the presence of T helper cells is necessary even in the late phase of tumor cell rejection in order to maintain protective immunity. However, despite the support of CD4(+) T helper cells, the tumor-specific CTL response is so weak that only at the site of tumor cell inoculation and not in the spleen or in the regional lymph nodes can TAg-specific CTL be detected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602701      PMCID: PMC114641          DOI: 10.1128/JVI.75.22.10593-10602.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  High gradient magnetic cell separation with MACS.

Authors:  S Miltenyi; W Müller; W Weichel; A Radbruch
Journal:  Cytometry       Date:  1990

2.  Interferon: a cytotoxic T lymphocyte differentiation signal.

Authors:  L K Chen; B Tourvieille; G F Burns; F H Bach; D Mathieu-Mahul; M Sasportes; A Bensussan
Journal:  Eur J Immunol       Date:  1986-07       Impact factor: 5.532

3.  Murine interleukin-4 displays potent anti-tumor activity in vivo.

Authors:  R I Tepper; P K Pattengale; P Leder
Journal:  Cell       Date:  1989-05-05       Impact factor: 41.582

4.  Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity.

Authors:  M Giovarelli; A Santoni; C Jemma; T Musso; A M Giuffrida; G Cavallo; S Landolfo; G Forni
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

5.  Evidence of a role for TNF-alpha in cytolysis by CD4+, class II MHC-restricted cytotoxic T cells.

Authors:  J P Tite
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

6.  Expression of simian virus 40 T antigen in insect cells using a baculovirus expression vector.

Authors:  R E Lanford
Journal:  Virology       Date:  1988-11       Impact factor: 3.616

Review 7.  Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes.

Authors:  S S Tevethia
Journal:  Mol Biol Med       Date:  1990-02

8.  The role of T cells in allografted tumor rejection: IFN-gamma released from T cells is essential for induction of effector macrophages in the rejection site.

Authors:  Y Yoneda; R Yoshida
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

9.  Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.

Authors:  M Nagarkatti; S R Clary; P S Nagarkatti
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

10.  Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo.

Authors:  M P Colombo; G Ferrari; A Stoppacciaro; M Parenza; M Rodolfo; F Mavilio; G Parmiani
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

View more
  6 in total

1.  Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 2.  Peptides for Vaccine Development.

Authors:  Ian W Hamley
Journal:  ACS Appl Bio Mater       Date:  2022-02-23

3.  An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses.

Authors:  Michael Bruns; Jara Wanger; Olaf Utermöhlen; Wolfgang Deppert
Journal:  Oncotarget       Date:  2015-11-17

Review 4.  Development of Peptide Vaccines in Dengue.

Authors:  Kavita Reginald; Yanqi Chan; Magdalena Plebanski; Chit Laa Poh
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

5.  Immunotherapy of WAP-TNP mice with early stage mammary gland tumors.

Authors:  Michael Bruns; Wolfgang Deppert
Journal:  Oncotarget       Date:  2017-06-29

6.  T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.

Authors:  Michael Bruns; Jara Wanger; Udo Schumacher; Wolfgang Deppert
Journal:  Oncotarget       Date:  2016-10-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.